載入中
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
前收盤價
US$0.4001
−US$0.0169 · -4.05%
盤中時間採用ET。市場資料可能有所延遲。
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$0.4001
52週區間
目前US$0.4001
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
58
合理估值
情緒
41
多空交錯
風險
84
極高風險
動能
29
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$0.4001
52週區間
目前US$0.4001
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 4.1萬 USD | — | 222.5萬 USD | 303.1萬 USD | 230.6萬 USD |
| 毛利 | −4.1萬 USD | — | −222.5萬 USD | −303.1萬 USD | −230.6萬 USD |
| 研究與開發 | 151.6萬 USD | 841.8萬 USD | 3918萬 USD | 6394.9萬 USD | 5353.9萬 USD |
| 銷售、一般及管理費用 | 394.8萬 USD | 413.5萬 USD | 932.1萬 USD | 1221萬 USD | 1101.7萬 USD |
| 營業費用 | 239.1萬 USD | 1624.5萬 USD | 4850.1萬 USD | 7312.8萬 USD | 6441.7萬 USD |
| 利息收入 | 51.1萬 USD | 18.4萬 USD | 85萬 USD | 68.9萬 USD | 36.8萬 USD |
| 利息支出 | — | −5000 USD | 131.4萬 USD | 335.9萬 USD | 1.5萬 USD |
| 折舊和攤銷 | 4.1萬 USD | 82.3萬 USD | 222.5萬 USD | 303.1萬 USD | 230.6萬 USD |
| 營業利益 | −243.2萬 USD | −1624.5萬 USD | −5072.6萬 USD | −7615.9萬 USD | −6672.3萬 USD |
| 淨利 | −192.1萬 USD | −1575.2萬 USD | −5160.2萬 USD | −7752.5萬 USD | −6637萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年1月16日 | 1:50 | — | — |
股票分割 | 2023年4月4日 | 1:15 | — | — |
已生效 2025年1月16日
1:50
已生效 2023年4月4日
1:15
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
